Yvonne M. Saenger

Yvonne M. Saenger, MD

  • Profesor asociado, Departamento de Oncología (Oncología Médica)
  • Profesor asociado, Departamento de Microbiología e Inmunología
  • Profesor asociado, Departamento de Patología
  • Director, Centro de Monitoreo Inmunológico
  • Director, Montefiore Einstein Comprehensive Cancer Center Immunotherapy Program
  • Codirector del Programa de Terapéutica del Cáncer del Centro Oncológico Integral Montefiore Einstein

Área de investigación

  • Biomarkers for early stage melanoma Immunotherapy for hepatocellular cancer Immunotherapy biomarkers for solid tumors

Correo electrónico

Teléfono

centro médico

  • Albert Einstein College of Medicine Jack and Pearl Resnick Campus 1300 Morris Park Avenue Golding Building 701 Bronx, NY 10461

¿Es usted un paciente?

Visitar perfil médico

Intereses profesionales

Dr. Yvonne Saenger is an expert in cancer immunotherapy with a focus on melanoma and gastro-intestinal tumors

The Saenger laboratory researches immune biomarkers for melanoma recurrence to stratify patients for adjuvant immunotherapy.  Digital pathology and artificial intelligence methods are used.

A second area of focus is analysis of the tumor immune micro-environment in liver cancer, particularly on studying human specimens and organoids to define the role of immune cell populations and complement in tumor progression.

Publicaciones Seleccionadas

Gartrell-Corrado RD, Chen A, Rizk EM , Marks DK, Bogardus M, Hart TD, Silverman AM, Bayan CA, Finkel G, Barker L , Komatsubara KM, Carvajal RD, Horst BA, Chang R, Monod A , Rabadán R, Saenger Y, “Linking transcriptomic and imaging data defines features of a favorable tumor immune microenvironment and identifies a combination biomarker for primary melanoma,” Cancer Research. 2020 Mar 1;80(5):1078-1087. PMID: 31948941

 

Kulkarni PM, Robinson EJ, Pradhan JS, Gartrell-Corrado RD, Rohr B, Kluger HM, Wong PF, Acs B, Rizk EM, Yanc C, Mondal M, Moore M, Phelps R, Hoorst BA, Ferringer T, Rimm DL, Wang J, Saenger Y, “Deep learning based on standard H&E images of primary melanoma tumors identifies patients at risk for visceral recurrence and death,” Clinical Cancer Research. 2019 Oct 21. Clinical Cancer Research.1495.2019. PMID: 31636101

 

Gartrell RD, Marks DK, Rizk EM, Bogardus M, Gerard CL, Barker LW, Fu Y, Esancy CL, Li G, Ji J, Rui S, Ernstoff MS, Taback B, Pabla S, Chang R, Lee SJ, Krolewski JJ, Morrison C, Horst B, Saenger YM, “Validation of Melanoma Immune Profile (MIP), a Prognostic Immune Gene Prediction Score for Stage II-III Melanoma,” Clinical Cancer Research, 2019 Jan 15 PMID: 30647081

 

Zhao J, Chen AX, Gartrell RD, Silverman A, Aparicio L, Chu T, Bordbar D, Shan D, Samanamud J, Goetz M, Yagamuchi JT, Cloney M, Horbinski C, Lukas RV, Raizer J, Rae AI, Yun J, Canoll P, Bruce JN, Saenger YM, Sims P, Iwamoto FB, Sonabend AM, Rabadan, R. “Longitudinal genomic study of response to anti-PD-1 immunotherapy in Glioblastoma Multiforme,” Nature Medicine 2019 Mar 25(3):462-469 PMID: 30742119

 

Gartrell RD, Marks DK, Hart TD, Li G, Davari DR, Wu A, Blake Z, Lu Y, Askin KN, Monod A, Esancy CL, Stack EC, Jia DT, Armenta PM, Fu Y, Izaki D, Taback B, Rabadan R, Kaufman HL, Drake CG, Horst BA, Saenger YM, “Quantitative Analysis of Immune Infiltrates in Primary Melanoma,” Cancer Immunol Res. 2018 Apr;6(4):481-493 PMID: 29467127

 

 

Gartrell RD, Enzler T, Kim PS, Fullerton BT, Fazlollahi L, Chen AX, Minns HE, Perni S, Weisberg SP, Rizk EM, Wang S, Oh EJ, Guo XV, Chiuzan C, Manji GA, Bates SE, Chabot J, Schrope B, Kluger M, Emond J, Rabadán R, Farber D, Remotti HE, Horowitz DP, Saenger YM. Neoadjuvant chemoradiation alters the immune microenvironment in pancreatic ductal adenocarcinoma, Oncoimmunology. 2022 May 5. PMID: 35558160